Published in Cardiovasc Drugs Ther on February 01, 1991
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation (2001) 7.47
Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation (2000) 5.09
The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg (1991) 4.53
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation (1995) 4.48
Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med (1998) 3.41
Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J (2002) 3.01
Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation (2000) 2.95
Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation (1998) 2.53
The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg (1991) 2.42
Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest (1980) 2.41
Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet (1995) 2.30
A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A (2000) 2.26
Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J (2002) 2.17
A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med (2000) 2.02
Demonstration of a widely distributed atrial pacemaker complex in the human heart. Circulation (1988) 1.91
Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines. Am J Physiol (1990) 1.89
Successful surgical treatment of atrial fibrillation. Review and clinical update. JAMA (1991) 1.89
Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ Res (1984) 1.83
Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J Biol Chem (2001) 1.78
Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol (2000) 1.74
Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel. Circ Res (2001) 1.72
Electrocardiographic prediction of abnormal genotype in congenital long QT syndrome: experience in 101 related family members. J Cardiovasc Electrophysiol (2001) 1.71
Molecular diagnosis in a child with sudden infant death syndrome. Lancet (2001) 1.66
Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: a key to sudden death during sleep? Ital Heart J (2000) 1.59
New mutations in the KVLQT1 potassium channel that cause long-QT syndrome. Circulation (1998) 1.53
Increased alpha-adrenergic receptors in ischemic cat myocardium. A potential mediator of electrophysiological derangements. J Clin Invest (1981) 1.51
Inferior vena cava loop of the implantable cardioverter defibrillator endocardial lead: a possible solution of the growth problem in pediatric implantation. Pacing Clin Electrophysiol (2000) 1.48
Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation (1992) 1.47
Mechanisms contributing to malignant dysrhythmias induced by ischemia in the cat. J Clin Invest (1978) 1.45
Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome. Hum Mol Genet (1999) 1.43
Brugada syndrome and sudden cardiac death in children. Lancet (2000) 1.40
Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium. J Clin Invest (1978) 1.34
Reentrant and nonreentrant mechanisms contribute to arrhythmogenesis during early myocardial ischemia: results using three-dimensional mapping. Circ Res (1987) 1.30
Autonomic neural influences on the dysrhythmias resulting from myocardial infarction. Circ Res (1978) 1.27
Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol (1999) 1.25
Mechanisms of I(Ks) suppression in LQT1 mutants. Am J Physiol Heart Circ Physiol (2000) 1.24
Disparate electrophysiological alterations accompanying dysrhythmia due to coronary occlusion and reperfusion in the cat. Circulation (1978) 1.23
The arrhythmogenic effects of caffeine in human beings. N Engl J Med (1983) 1.22
Electrophysiologic mechanisms underlying arrhythmias due to reperfusion of ischemic myocardium. Circulation (1987) 1.20
Protective effect of vagal stimulation on reperfusion arrhythmias in cats. Circ Res (1987) 1.20
Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol (2001) 1.12
Alpha adrenergic-mediated accumulation of calcium in reperfused myocardium. J Clin Invest (1983) 1.09
Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol (1991) 1.07
Electrophysiologic basis, surgical development, and clinical results of the maze procedure for atrial flutter and atrial fibrillation. Adv Card Surg (1995) 1.07
Pathophysiological concentrations of lysophosphatides and the slow response. Am J Physiol (1982) 1.06
Long-chain acylcarnitine induces Ca2+ efflux from the sarcoplasmic reticulum. J Cardiovasc Pharmacol (2000) 1.05
Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Physiol (1994) 1.05
Electrophysiological effects of amphiphiles on canine purkinje fibers. Implications for dysrhythmia secondary to ischemia. Circ Res (1981) 1.04
Potential arrhythmogenic electrophysiological derangements in canine Purkinje fibers induced by lysophosphoglycerides. Circ Res (1979) 1.02
Enhanced alpha-adrenergic responsiveness in ischemic myocardium: role of alpha-adrenergic blockade. Am Heart J (1981) 1.01
Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischemic myocardium. Circulation (1983) 1.01
Behavioral parameters of drug action: signaled and response-independent reinforcement. J Exp Anal Behav (1974) 1.01
CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis (2013) 1.01
The dependence of electrophysiological derangements on accumulation of endogenous long-chain acyl carnitine in hypoxic neonatal rat myocytes. Circ Res (1986) 1.01
Torsade de pointes. Mechanisms and management. Drugs (1994) 1.01
Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. Am J Physiol Heart Circ Physiol (2000) 1.00
Arrhythmogenic amphiphilic lipids and the myocardial cell membrane. J Mol Cell Cardiol (1982) 1.00
Intramural reentry as a mechanism of ventricular tachycardia during evolving canine myocardial infarction. Circ Res (1985) 1.00
Cellular uncoupling induced by accumulation of long-chain acylcarnitine during ischemia. Circ Res (1994) 0.99
Mechanisms underlying the development of ventricular fibrillation during early myocardial ischemia. Circ Res (1990) 0.98
Palmitoylcarnitine increases [Na+]i and initiates transient inward current in adult ventricular myocytes. Am J Physiol (1995) 0.96
Rapid activation of the sympathetic nervous system following coronary artery occlusion: relationship to infarct size, site, and haemodynamic impact. Cardiovasc Res (1979) 0.96
Voltage-gated Na+ channel activity and connexin expression in Cx43-deficient cardiac myocytes. J Cardiovasc Electrophysiol (1999) 0.95
Role of the vagus nerves in the cardiovascular changes induced by coronary occlusion. Circulation (1974) 0.95
Computerized global electrophysiological mapping of the atrium in patients with Wolff-Parkinson-White syndrome. Ann Thorac Surg (1988) 0.95
Long-chain acylcarnitines mediate the hypoxia-induced increase in alpha 1-adrenergic receptors on adult canine myocytes. Circ Res (1987) 0.93
Dissociation between cellular K+ loss, reduction in repolarization time, and tissue ATP levels during myocardial hypoxia and ischemia. Circ Res (1993) 0.92
Influence of long-chain acylcarnitines on voltage-dependent calcium current in adult ventricular myocytes. Am J Physiol (1992) 0.92
Alterations of intercellular junctions induced by hypoxia in canine myocardium. Am J Physiol (1990) 0.92
Computerized global electrophysiological mapping of the atrium in a patient with multiple supraventricular tachyarrhythmias. Ann Thorac Surg (1988) 0.91
Inhibition of gap junctional conductance by long-chain acylcarnitines and their preferential accumulation in junctional sarcolemma during hypoxia. Circ Res (1993) 0.90
Lysophosphatidyl choline potentiates Ca2+ accumulation in rat cardiac myocytes. Am J Physiol (1983) 0.89
Site of myocardial infarction. A determinant of the cardiovascular changes induced in the cat by coronary occlusion. Circ Res (1976) 0.89
Beta-adrenergic-mediated influences on microscopic conduction in epicardial regions overlying infarcted myocardium. Circ Res (1990) 0.88
Lysophosphoglycerides in ischemic myocardium effluents and potentiation of their arrhythmogenic effects. Am J Physiol (1981) 0.88
Induction of delayed afterdepolarizations and triggered activity in canine Purkinje fibers by lysophosphoglycerides. Circ Res (1986) 0.87
Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping. J Pharmacol Exp Ther (1991) 0.87
Incorporation of radiolabeled lysophosphatidyl choline into canine Purkinje fibers and ventricular muscle. Electrophysiological, biochemical, and autoradiographic correlations. Circ Res (1982) 0.87
Enhanced inositol trisphosphate response to alpha 1-adrenergic stimulation in cardiac myocytes exposed to hypoxia. J Clin Invest (1989) 0.87
Computerized activation sequence mapping of the human atrial septum. Ann Thorac Surg (1990) 0.86
Anion exchange chromatographic separation of inositol phosphates and their quantification by gas chromatography. Anal Biochem (1989) 0.85
Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol (1998) 0.85
Arrhythmias associated with reperfusion: basic insights and clinical relevance. J Cardiovasc Pharmacol (1984) 0.85
Electrophysiologic effects of intracellular lysophosphoglycerides and their accumulation in cardiac lymph with myocardial ischemia in dogs. J Clin Invest (1986) 0.84
Pathophysiologic concentrations of lysophosphoglycerides quantified by electron microscopic autoradiography. Lab Invest (1984) 0.84
Activation of thrombin receptor increases intracellular Na+ during myocardial ischemia. Am J Physiol (1995) 0.84
The arachidonic acid metabolic capacity of canine myocardium is increased during healing of acute myocardial infarction. Circ Res (1982) 0.84
Surgery for atrial fibrillation. Semin Thorac Cardiovasc Surg (1989) 0.83
Recent insights pertaining to sarcolemmal phospholipid alterations underlying arrhythmogenesis in the ischemic heart. J Cardiovasc Electrophysiol (1993) 0.83
Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes (1994) 0.83
Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol (1995) 0.83
Arrhythmogenesis and ventricular dysfunction after myocardial infarction. Is anomalous cellular coupling the elusive link? Circulation (1993) 0.82
Influences of labetalol a combined alpha- and beta-adrenergic blocking agent on the dysrhythmias induced by coronary occlusion and reperfusion. Cardiovasc Res (1982) 0.82
Alpha 1-adrenergic system and arrhythmias in ischaemic heart disease. Eur Heart J (1991) 0.81
Operations for atrial fibrillation. Clin Cardiol (1991) 0.81
Adrenergic factors in arrhythmogenesis in the ischemic and reperfused myocardium. Eur Heart J (1983) 0.81
Contribution of shrinkage of extracellular space to extracellular K+ accumulation in myocardial ischaemia of the rabbit. J Physiol (1996) 0.81
Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome. Circulation (1999) 0.80
Augmentation of cyclic AMP content induced by lysophosphatidyl choline in rabbit hearts. Cardiovasc Res (1979) 0.80